How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,657 results for

Medication Causes of Headache

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Full Text available with Trip Pro

migraine therapies, and patient-reported effects. Migraine headache frequency decreased from 10.4 to 4.6 headaches per month (p<0.0001) with the use of medical marijuana. Most patients used more than one form of marijuana and used it daily for prevention of migraine headache. Positive effects were reported in 48 patients (39.7%), with the most common effects reported being prevention of migraine headache with decreased frequency of migraine headache (24 patients [19.8%]) and aborted migraine headache (...) effects compared with other forms.The frequency of migraine headache was decreased with medical marijuana use. Prospective studies should be conducted to explore a cause-and-effect relationship and the use of different strains, formulations, and doses of marijuana to better understand the effects of medical marijuana on migraine headache treatment and prophylaxis.© 2016 Pharmacotherapy Publications, Inc.

2016 Pharmacotherapy

62. Medication-overuse Headache: The Effect of a Patient Educational Programme as an add-on to Standard Treatment

(RCT) design. Condition or disease Intervention/treatment Phase Secondary Headache Disorders Medication-overuse Headache Behavioral: Educational programme Not Applicable Detailed Description: Worldwide, two percent of the population suffers from medication-overuse headache (MOH), a paradox condition where the headache is caused by overuse of headache medication. Common treatment is withdrawal, but there is no consensus on what constitutes the best treatment. The study consists of a RCT with MOH (...) provided by Louise Schlosser Mose, Hospital of South West Denmark: Medication-overuse Headache Educational Programme Personality Profiles Additional relevant MeSH terms: Layout table for MeSH terms Headache Headache Disorders Headache Disorders, Secondary Pain Neurologic Manifestations Signs and Symptoms Brain Diseases Central Nervous System Diseases Nervous System Diseases

2016 Clinical Trials

63. Is septoplasty effective rhinogenic headache in patients with isolated contact point between inferior turbinate and septal spur? (Abstract)

Is septoplasty effective rhinogenic headache in patients with isolated contact point between inferior turbinate and septal spur? Rhinogenic headache is a painful sensation in the head and face due to intranasal contact point without any mass or inflammatory findings. Surgery is recommended in patients with nasal obstruction; however the approach in case of isolated mucosal contact point that does not cause obstruction is controversial. Our aim is to observe changes in the severity of headache (...) was recommended to the patients with no satisfactory relieve of headache. Visual Analog Scales (VAS) were used to evaluate the severity of headache in patients at time of diagnosis (0 month), after a medical treatment (1st month) and after a surgical or medical treatment (6th month). The results were compared with each other statistically.There was a decrease in VAS values after a month of medical treatment in all patients with isolated contact point (Z = -8.352; p = 0.0). VAS values significantly improved

2019 American Journal of Otolaryngology

64. Rhinogenic headache in pediatric and adolescent patients: an evidence-based review. (Abstract)

Rhinogenic headache in pediatric and adolescent patients: an evidence-based review. Although some causes of rhinogenic headache, such as acute sinusitis, have clear diagnostic criteria, others, such as "sinus headache" and mucosal contact points, are more nebulous. Misdiagnosis of these entities and primary headaches may result in unnecessary medical or surgical treatment. The purpose of this systematic review is to delineate current understanding of diagnosis and treatment of rhinogenic (...) was predominantly 4. Forty percent of pediatric patients with migraine had been previously misdiagnosed with sinus headache. Of 327 pediatric patients in two studies, between 55% and 73% had at least 1 cranial autonomic symptom associated with their migraine. For children with mucosal contact point headaches, surgical management in select patients improved headache intensity or severity in 17 (89%) cases.The majority of pediatric patients with sinus headache harbor a primary headache disorder, with migraine

2019 International forum of allergy & rhinology

65. Non-pharmacological Management of Persistent Headaches Associated with Neck Pain: A Clinical Practice Guideline from the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Full Text available with Trip Pro

benefits, cost-effectiveness, societal and ethical values, and patient experiences when formulating recommendations. Target audience includes clinicians; target population is adults with persistent headaches associated with neck pain.When managing patients with headaches associated with neck pain, clinicians should (a) rule out major structural or other pathologies, or migraine as the cause of headaches; (b) classify headaches associated with neck pain as tension-type headache or cervicogenic headache (...) visit to assess outcomes and determine whether a referral is indicated.Our evidence-based guideline provides recommendations for the conservative management of persistent headaches associated with neck pain. The impact of the guideline in clinical practice requires validation.Neck pain and headaches are very common comorbidities in the population. Tension-type and cervicogenic headaches can be treated effectively with specific exercises. Manual therapy can be considered as an adjunct therapy

2019 European Journal of Pain

66. The role of the otolaryngologist in the evaluation and management of headaches. (Abstract)

MEDLINE, Cochrane Library, and Google Scholar databases.A literature search was performed to identify relevant articles published in the past 10 years addressing the diagnosis and management of rhinogenic headache, trigeminal neuralgia and/or migraine.Rhinogenic headache: Identification of the specific cause must be achieved before treatment. No studies have mentioned the effect of certain therapies on the amelioration of headache. New techniques of balloon dilation for sinusitis are controversial (...) , and their use remains contingent on surgeon preference. Removal of mucosal contact points has been shown to benefit quality of life in patients with contact point headache. Trigeminal neuralgia: Microvascular decompression is considered the gold standard for treatment, but percutaneous therapies can be effective for achieving pain control. Migraine: Patients who report amelioration of symptoms after targeted botulinum toxin injection may benefit from definitive decompression or nerve avulsion. Patients

2019 American Journal of Otolaryngology

67. Is Forward Head Posture Cause Balance Dysfunctions in Subjects with Chronic Neck Pain?: Systematic Review.

Is Forward Head Posture Cause Balance Dysfunctions in Subjects with Chronic Neck Pain?: Systematic Review. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

68. Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT). Drug: Systemic Therapy Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after (...) Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2018 Clinical Trials

69. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

the course of their illness. Metastases to the bone can cause accelerated bone breakdown which may result in pain, pathologic fracture and nerve or spinal cord compression resulting in sensory loss or motor weakness. Laboratory abnormalities may include hypercalcemia and myelosuppression. Radiation therapy has long been used to palliate pain and other symptoms of bone metastases with excellent results. There have been multiple prospective, randomized, controlled clinical trials comparing different (...) for medical necessity review , due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner. CPT ® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT ® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data

2018 AIM Specialty Health

70. Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache?

, Relative risk of bene?t with sumatriptan compared with placebo; CI, con?dence interval; NNT, number needed to treat. ANNALS OF EMERGENCY MEDICINE JULY 2013 Volume ??, ??. ? : July ???? Annals of Emergency Medicine 11Commentary Migraines are a disabling headache disorder affecting up to 5% of men and 17% of women. 2 Migraines cause considerable impairment in terms of pain, disability, social functioning, re- lationships,emotionalwell-being,and general health. 3-5 It is estimated that migraine headaches (...) for less rescue medication. However, sumatriptan was also found to have more adverse events, such as sensa- tions of heat, tingling, chest disco- mfort, and injection-site reactions, even though they tended to be self- limiting. Comparison of subcutaneous sumatriptan versus placebo. Outcome RR (95% CI) NNT (95% CI) No. of Attacks Treated Pain free at 1 h 5.5 (4.5–6.8) 2.9 (2.7–3.2) 3,592 Headache relief at 1 h 2.7 (2.5–2.9) 2.2 (2.1–2.4) 5,177 24-h sustained pain free 2.2 (1.6–2.9) 6.1 (4.8–8.2) 752 RR

2013 Annals of Emergency Medicine Systematic Review Snapshots

71. Medication Overuse Headache (MOH) and an Innovative Approach

Technology (ICT) system that allows patients with a chronic condition to receive continuous and personalized treatment. The whole system is based on an advanced, "all in one" Alerting and Decision Support System that follows patients from the diagnosis and supports the physician in managing the therapy, controlling relevant events impacting on patient safety and activating specific procedures if selected thresholds are exceeded. In the frame of chronic neurological disorders, Medication Overuse Headache (...) of Medication Overuse Headache in Europe and Latin America: Development and STAndardization of an Alert and Decision Support System Study Start Date : July 2008 Actual Primary Completion Date : July 2009 Actual Study Completion Date : June 2010 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment No Intervention: Classic Approach Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute

2015 Clinical Trials

72. Headache - cluster

listed below should be considered: Headache not associated with an underlying condition – primary headache: Migraine . Tension-type headache . Trigeminal autonomic cephalalgias other than cluster headache such as paroxysmal hemicranias. Other primary headache disorders such as primary cough headache and cold-stimulus headache. Secondary headachesheadache attributed to an underlying condition including: Trauma or injury to the head and/or neck . Cranial or cervical vascular disorders for example (...) Disorders 3rd edition (Beta version). . Kristoffersen ES, Lundqvist C ( 2014 ) Medication-overuse headache: epidemiology, diagnosis and treatment. Therapeutic advances in drug safety 5 ( 2 ), 87 - 99 . Law S, Derry S, Moore RA ( 2013 ) Triptans for acute cluster headache. John Wiley & Sons, Ltd. . Miller S, Matharu MS ( 2013 ) Managing patients with cluster headache in primary care. Practitioner 257 ( 1764 ), 15 - 20 . Millstine D, Chen CY, Bauer B ( 2017 ) Complementary and integrative medicine

2017 NICE Clinical Knowledge Summaries

73. Headache - tension-type

months. Tension-type headache typically presents with: Generalised headache usually described as a pressure or tightness around the head which often spreads into or arises from the neck. Mild to moderate intensity headache which can last minutes to days and is not aggravated by routine physical activity such as walking. Pericranial tenderness which may be elicited on manual palpation. The cause of tension-type headache is unknown — peripheral pain mechanisms are thought to play a role in episodic (...) also be considered: Headache not associated with an underlying condition – primary headache: Migraine . Trigeminal autonomic cephalgias for example cluster headache and paroxysmal hemicranias. Other primary headache disorders such as primary cough headache and cold-stimulus headache. Secondary headachesheadache attributed to an underlying condition including: Trauma or injury to the head and/or neck . Cranial or cervical vascular disorders for example intracerebral haemorrhage, central venous

2017 NICE Clinical Knowledge Summaries

74. Headache - assessment

, medication overuse or neoplasm. Assessment of headache can be complicated by the co-existence of more than one type of headache and separate histories are needed for each. The clinician should be alert for any signs or symptoms suggestive of a serious underlying cause of headache requiring emergency or urgent referral to secondary care. The history should include questions on: Onset, duration, frequency and temporal pattern of the headache. Pain characteristics including severity, site and spread of pain (...) . Trigeminal autonomic cephalgias such as cluster headache. Other primary headache disorders such as primary cough headache or cold-stimulus headache. Secondary headachesheadaches which occur as a result of underlying local or systemic pathology for example: Trauma or injury to the head and/or neck. Cranial or cervical vascular disorders such as intracerebral haemorrhage, central venous thrombosis or giant cell arteritis. Non-vascular intracranial disorders such as idiopathic intracranial hypertension

2017 NICE Clinical Knowledge Summaries

75. Review of the New Strategic Direction for Alcohol and Drugs – Phase 2

Review of the New Strategic Direction for Alcohol and Drugs – Phase 2 The Institute of Public Health in Ireland 1 Review of the New Strategic Direction for Alcohol and Drugs – Phase 2 A report prepared for the Department of Health in Northern Ireland by the Institute of Public Health in Ireland 1 Institute of Public Health in Ireland Review of the New Strategic Direction for Alcohol and Drugs – Phase 2 2018 A report prepared for the Department of Health in Northern Ireland by the Institute (...) of Public Health in Ireland To be cited as: Purdy, J. Cummins, H. and McAvoy, H. (2018) Review of the New Strategic Direction for Alcohol and Drugs – Phase 2. Dublin: Institute of Public Health in Ireland. Report available at www.publichealth.ie The Institute of Public Health in Ireland has produced this document as a resource for public health on this island. It may be freely reproduced with acknowledgement but is not for resale or for use in conjunction with commercial purposes. ISBN: TBC D.O.I: TBC

2019 Institute of Public Health in Ireland

76. Closed-system transfer-devices for limiting exposure to cytotoxic anti-cancer drugs in healthcare professionals, patients and visitors

, the clinical importance of this reduction is unknown. ? Four studies reporting a range of guidelines for the safe-handling of hazardous drugs recommended implementation of training, personal protective equipment (PPE), CSTDs, medical surveillance and other safety measures, largely based on expert consensus. SHTG Evidence Synthesis | 3 Contents Definitions 4 Literature search 4 Introduction 4 Description of health problem 6 Health technology description 6 Clinical effectiveness 7 Cost effectiveness 14 (...) Organisational issues/context 15 Identified research gaps 16 Conclusion 16 Equality and diversity 17 Acknowledgements 17 References 18 SHTG Evidence Synthesis | 4 Definitions Antineoplastic: Blocking the formation of neoplasms (growths that may become cancer) 1 . Cytotoxic drug: A substance that kills cells, including cancer cells. These agents may stop cancer cells from dividing and growing and may cause tumors to shrink in size 1 . Carcinogen: Any substance that causes cancer 1 . Genotoxic: Denoting

2019 SHTG Advice Statements

77. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia

, aggression, pacing, walking about, altered sexual behaviour, changed sleep patterns, and appetite disturbances. Non-pharmacological Interventions such as music therapy, relaxation, distraction techniques, and massage, or with cognitive and behavioural interventions, as opposed to pharmacological/medication interventions. Off label The use of medications for an unapproved indication or in an unapproved age group, dosage, or route of administration. Parkinson’s disease dementia The brain changes caused (...) Grading of Recommendations Assessment, Development and Evaluation GDG Guideline Development Group GDP Global Domestic Product MCI Mild Cognitive Impairment MHBC Ministry of Health British Columbia MHRA Medicines and Healthcare products Regulatory Agency NCEC National Clinical Effectiveness Committee NHMRC National Health and Medical Research Council NHS National Health Service NICE National Institute for Health and Care Excellence NPI Neuropsychiatric Inventory PBS Pharmaceutical Benefit Scheme PDD

2019 National Clinical Guidelines (Ireland)

78. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation Full Text available with Trip Pro

., Dorn, S.D. et al. American Gastroenterological Association medical position statement on constipation. Gastroenterology . 2013 ; 144 : 211–217 | | | | | Once a diagnosis of OIC has been confirmed and other potential causes of constipation are excluded, the recommendations here can help guide appropriate evidence-based management. This guideline focuses on the medical management of OIC. Therefore, it does not address the role of psychological therapy, alternative medicine approaches, surgery (...) control, the AGA recommends escalation of therapy to PAMORA drugs with high- or moderate-quality evidence of efficacy, namely naldemedine and naloxegol. The AGA also conditionally recommends use of methylnatrexone. Due to insufficient evidence, the AGA did not issue a recommendation regarding use of either lubiprostone or prucalopride in OIC. The recommendations are similar to those proposed by recent clinical guidelines related to OIC published by the American Academy of Pain Medicine x 25 Muller

2019 American Gastroenterological Association Institute

79. Are There Pharmacologic Agents That Safely and Effectively Treat Post-lumbar Puncture Headache?

Rawle A. Seupaul, MD Department of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Of 1,615 studies identi?ed by the pri- mary search strategy, 27 were re- viewed, yielding 7 trials (total of 200 subjects)thatmetinclusioncriteria.A meta-analysis was not performed be- cause none of the studies compared similar interventions and the out- comes reported were variable. Only 1 trial, 3 studying intravenous caffeine, reported on persistent postural head- ache (...) Visual analog score at 1 h (100-point scale) 18.0 (55.7 to 19.7) Intravenous caffeine 3 41 Persistent headache at 1–2 h Absolute risk reduction: 0.61 (0.37 to 0.85) *Each row represents 1 study because no therapy was tested in more than 1 included study. ANNALS OF EMERGENCY MEDICINE JANUARY 2013 84 Annals of Emergency Medicine Volume ??, ??. ? : January ????reported to occur in 3% to 36% of lumbar punctures 4 (with higher rates occurring when a traumatic needle is used) and may require symptomatic

2012 Annals of Emergency Medicine Systematic Review Snapshots

80. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)

, Scotland and Northern Ireland on Deep brain stimulation for refractory chronic pain syndromes (excluding headache). NICE has also published guidance on (NICE interventional procedure guidance 381, March 2011). Description Refractory chronic pain syndromes are characterised by pain that persists despite treatment and for longer than expected. Causes are varied and pain can occur anywhere in the body. Chronic pain can be debilitating and have a significant impact on a person’s quality of life. A variety (...) Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382) Overview | Deep brain stimulation for refractory chronic pain syndromes (excluding headache) | Guidance | NICE Deep brain stimulation for refractory chronic pain syndromes (excluding headache) Interventional procedures guidance [IPG382] Published date: March 2011 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales

2011 National Institute for Health and Clinical Excellence - Interventional Procedures

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>